246 related articles for article (PubMed ID: 20833412)
1. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study.
Barsoum MK; Heit JA; Ashrani AA; Leibson CL; Petterson TM; Bailey KR
Thromb Res; 2010 Nov; 126(5):373-8. PubMed ID: 20833412
[TBL] [Abstract][Full Text] [Related]
2. Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.
Ashrani AA; Barsoum MK; Crusan DJ; Petterson TM; Bailey KR; Heit JA
Thromb Res; 2015 Jun; 135(6):1110-6. PubMed ID: 25891841
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.
Ashrani AA; Gullerud RE; Petterson TM; Marks RS; Bailey KR; Heit JA
Thromb Res; 2016 Mar; 139():29-37. PubMed ID: 26916293
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives and venous thromboembolism. A case-control study.
Lidegaard O; Edström B; Kreiner S
Contraception; 1998 May; 57(5):291-301. PubMed ID: 9673836
[TBL] [Abstract][Full Text] [Related]
7. Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
Rott H
Hamostaseologie; 2019 Feb; 39(1):42-48. PubMed ID: 30669160
[TBL] [Abstract][Full Text] [Related]
8. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.
Sweetland S; Beral V; Balkwill A; Liu B; Benson VS; Canonico M; Green J; Reeves GK;
J Thromb Haemost; 2012 Nov; 10(11):2277-86. PubMed ID: 22963114
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
13. Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study.
Heit JA; Leibson CL; Ashrani AA; Petterson TM; Bailey KR; Melton LJ
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1399-405. PubMed ID: 19542020
[TBL] [Abstract][Full Text] [Related]
14. The association of active cancer with venous thromboembolism location: a population-based study.
Tafur AJ; Kalsi H; Wysokinski WE; McBane RD; Ashrani AA; Marks RS; Crusan DJ; Petterson TM; Bailey KR; Heit JA
Mayo Clin Proc; 2011 Jan; 86(1):25-30. PubMed ID: 21193652
[TBL] [Abstract][Full Text] [Related]
15. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
16. Are myocardial infarction and venous thromboembolism associated? Population-based case-control and cohort studies.
Barsoum MK; Cohoon KP; Roger VL; Mehta RA; Hodge DO; Bailey KR; Heit JA
Thromb Res; 2014 Sep; 134(3):593-8. PubMed ID: 25037496
[TBL] [Abstract][Full Text] [Related]
17. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
18. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
Renoux C; Dell'Aniello S; Brenner B; Suissa S
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
[TBL] [Abstract][Full Text] [Related]
19. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
[TBL] [Abstract][Full Text] [Related]
20. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study.
Cohoon KP; Ashrani AA; Crusan DJ; Petterson TM; Bailey KR; Heit JA
Am J Med; 2018 Mar; 131(3):307-316.e2. PubMed ID: 28987552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
